Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label escalating-dose study of PSD506 in detrusor hyper-reflexia due to spinal cord injury
2006-002663-11Phase 2Completed
- Sponsor
- Plethora Solutions
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PSD506 in detrusor hyperreflexia (DH) and neurogenic bladder, sponsored by Plethora Solutions. Primary endpoints: Reduction of unstable urinary bladder detrusor contractions and Safety of PSD506. Started Feb 2008; status: completed.
02
Drugs
PSD506
03
Conditions
detrusor hyperreflexia (DH)neurogenic bladder
Beyond the preview
Go deeper on 2006-002663-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002663-11.